Clinical Trials Logo

Clinical Trial Summary

Vascular diseases (cardiac events, strokes, peripheral vascular disease) remain the number one killer in Canadian society as well as the leading cause of hospitalization and days spent in the hospital. A 1996 estimate placed Ontario's vascular disease financial burden at $5.5 billion in total. Any intervention which lowers vascular risk, will have a direct impact on the quantity and quality of life and costs of health care. Further integration of health professionals in teams focused on chronic disease management in individuals and populations is also ripe for further evaluation. Increased collaboration between family physicians, physician specialists, nurse practitioners, and pharmacists are generally thought to be beneficial for patient outcomes, but the literature is inconclusive and their cost-effectiveness is unproven. In addition, combining centralized electronic up-to-date information on the patient's status with evidence-based recommendations and the ability to communicate either electronically or by phone is expected to result in improved access to care, quality of care, continuity of care and increase cost-effectiveness of chronic disease management.

COMPETE III builds on the researchers' previous work to study an electronic vascular tracking and decision support system shared by patients and their physicians, combined with a clinical care coordinator and automated telephone support system. The researchers are evaluating its impact on vascular risk processes and outcomes, perceived usefulness, ease of use, need for improvement, medication adherence, quality of life and patient goals and motivation.

Study hypothesis: Patients at increased risk of vascular events, if connected with their family physicians, medical specialists and care coordinator via an electronic network (Web, fax and telephone) sharing an intensive tracking, advice and support program, will lower their vascular risk more than those in usual care.


Clinical Trial Description

COMPETE is Canada's original electronic medical record research network and specializes in the rigorous development, implementation and evaluation of electronic technologies in health care. COMPETE III will build on COMPETE II to incorporate the latest evidence on:

1. the management of diabetes, hypertension, dyslipidemia and previous vascular events,

2. improving patient-clinician interactions,

3. the use of technology to enhance the quality, safety and efficiency of care and

4. motivational strategies to change both patient and clinician behaviour.

Specifically, the researchers will:

1. Expand the disease focus to a vascular risk population (diabetes, hypertension, dyslipidemia or previous vascular event);

2. Expand the electronic care network beyond patients and primary care providers to also include specialists (physician specialists, specialty nurse clinicians, etc);

3. Expand the geographical network from Hamilton area, and Ottawa to include other primary care reform (PCR), Ontario Family Health Networks (OFHN) or EHR using sites;

4. Tighten the integration with the leading Ontario EHR products and concentrate on those meeting the new Ontario Smart Systems for Health Clinical Management System specifications,

5. Strengthen the clinical decision support by offering evidence-based algorithms specific to the patient, provide specific formulary advice - drug listing, Limited Use prescriptions and codes, Section 8 criteria and form letters;

6. Improve the researchers pharmacosurveillance network which pursues reasons for starting and stopping medications by seeking adherence information directly from patients;

7. Provide direct links via Internet for patients and clinicians to best evidence about vascular disease,

8. Improve the automated telephone support (ATS);

9. Support physicians in managing this advanced care network by providing clinical care coordinators, either nurse clinicians or clinical pharmacists;

10. Use HL-7 messaging standards as per Canada Health Infoway guidelines;

11. Rigorously evaluate the cost-effectiveness of our package intervention in order to provide specific advice to health planners and payers on costs and benefits. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT00132145
Study type Interventional
Source St. Joseph's Healthcare Hamilton
Contact
Status Completed
Phase N/A
Start date April 2003
Completion date June 2006

See also
  Status Clinical Trial Phase
Recruiting NCT05971407 - The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01684826 - X-ray Dose Reduction Study for Cardiac Angiography and Intervention N/A
Completed NCT01417910 - Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients N/A
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Unknown status NCT01748383 - The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction) Phase 2
Recruiting NCT05907564 - Aventus Thrombectomy System Pulmonary Embolism Clinical Study N/A
Recruiting NCT03732612 - Inflammation in Vascular Disease
Completed NCT00000614 - Prevention of Recurrent Venous Thromboembolism (PREVENT) Phase 3
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00000539 - Arterial Disease Multifactorial Intervention Trial (ADMIT) Phase 3
Completed NCT00000474 - Prevention and Treatment of Hypertension Study (PATHS) Phase 3
Completed NCT00000528 - Trials of Hypertension Prevention (TOHP) Phase 3
Completed NCT00000509 - Potassium and Sodium to Control Blood Pressure in Hypertensives Phase 3
Completed NCT00000501 - Hypertension Prevention Trial (HPT) Feasibility Study Phase 2
Completed NCT00000499 - Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study) Phase 2